First Phase III trial of a generative-AI-discovered drug doses first patient
Event confirmedAwaiting review
Importance: major (4 of 5)Status
- Claim
Event confirmedAwaiting review
- Our reporting
- High confidence
- Verification
- Peer-reviewed
- Importance
- Major (4 of 5)
- Last verified
- 7 October 2026
Your AI and this story
- GPT-6 Astra133 days after its cutoff
- Claude Opus 5.572 days after its cutoff
- Gemini 4 Hydrogen163 days after its cutoff
- Grok 4.7102 days after its cutoff
None of these four assistants can know about it. The closest, Claude Opus 5.5, stops 72 days before it.
Key facts
- First patients dosed 2026-09-10 at Peking Union Medical College Hospital and Shanghai Pulmonary Hospital
- Randomized, double-blind, placebo-controlled; 320 participants; 47 centers in China; once daily for 52 weeks
- Primary endpoint: annual rate of FVC decline over 52 weeks; key secondary: time to first disease-progression event
- Phase IIa (Nature Medicine, 2025): 60 mg QD arm showed mean FVC +98.4 mL at 12 weeks, dose-dependent trend
- Mechanism: TNIK inhibition (target also identified by Insilico’s AI platform)
- Pipeline context: on 2026-01-23 the FDA cleared Insilico’s IND for ISM8969, an oral brain-penetrant NLRP3 inhibitor for Parkinson’s disease discovered and optimized with its Chemistry42 generative-chemistry engine (Phase I in healthy volunteers; co-developed 50/50 with Hygtia Therapeutics, which also won China NMPA IND clearance)
What happened
Insilico’s rentosertib is the furthest-advanced drug in which both the target and the molecule came from generative AI. Phase III is the final stage before regulatory approval.
Why it matters
If positive (results likely 2027+), it would be the first approved generative-AI-discovered drug — the key proof point for AI drug discovery’s promise to cut time and cost.
What is disputed or not yet verified
| Verification | Phase IIa trial results peer-reviewed in Nature Medicine (June 2025); Phase III efficacy not yet shown |
|---|
Sources
6 sources from 4 sites. Numbers match the chips in the text.
6 sources: 3 primary, 3 press
Primary
- Insilico: first patient dosed in GENESIS-IPF-3insilico.com, official
- PR Newswire: Insilico initiates Phase III trial for rentosertibprnewswire.com, official
- Insilico: IND approval from FDA for ISM8969 (Jan 23, 2026)insilico.com, official
Press
- EurekAlert: Nature Medicine publishes rentosertib Phase IIa results (June 2025)eurekalert.org, press
- Drug Target Review: Insilico begins Phase III of AI-designed drugdrugtargetreview.com, press
- EurekAlert: ISM8969/HT-001 receives NMPA IND clearanceeurekalert.org, press
Changes
- Science block: kind: other (not a long-open problem; listed with other AI science results, not in the open-problems count); verification reworded: only the Phase IIa results are peer-reviewed, Phase III efficacy is not yet shown
- Added ISM8969 FDA IND clearance (Jan 2026) as pipeline context; too routine for its own entry
- Added science block (science & math tab)
- Filed